Furthermore, tirzepatide, a dual GIP and GLP‐1 receptor agonist, is a valuable therapeutic option for managing T2D in adults alongside diet and exercise due to its ability to target two receptors. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.